# High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study

> **NCT03188978** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Albany Medical College**

## Conditions studied

- Primary Arteriovenous Fistula Failure

## Interventions

- **DRUG:** Atorvastatin 40mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03188978
- **Lead sponsor:** Albany Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to recruit
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188978, "High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03188978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*